Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLNN Clene	$5.33 -5.9%	$3.94	$2.28 ▼ $6.90	$53.20M	0.55	75,864 shs	103,855 shs
DWTX Dogwood Therapeutics	$5.01 +1.3%	$4.83	$1.62 ▼ $29.28	$9.58M	1.8	1.70 million shs	7,436 shs
MRSN Mersana Therapeutics	$7.66 -1.1%	$7.84	$5.21 ▼ $70.75	$38.25M	0.83	160,273 shs	72,201 shs
XLO Xilio Therapeutics	$0.70 -0.6%	$0.69	$0.62 ▼ $1.70	$36.23M	-0.15	2.06 million shs	137,769 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLNN Clene	0.00%	+56.35%	+55.07%	+138.82%	+4.81%
DWTX Dogwood Therapeutics	0.00%	+0.41%	+3.77%	-5.53%	+494,999,900.00%
MRSN Mersana Therapeutics	0.00%	+8.24%	-3.76%	-12.01%	-80.13%
XLO Xilio Therapeutics	0.00%	-0.83%	+0.92%	-20.45%	-22.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLNN Clene	3.2131 of 5 stars	3.6	4.0	0.0	2.1	2.5	0.6
DWTX Dogwood Therapeutics	1.7645 of 5 stars	3.5	0.0	0.0	2.3	0.0	0.6
MRSN Mersana Therapeutics	4.196 of 5 stars	3.5	4.0	4.1	1.8	2.5	0.0
XLO Xilio Therapeutics	2.655 of 5 stars	3.7	2.0	0.0	1.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLNN Clene	3.17	Buy	$33.00	519.72% Upside
DWTX Dogwood Therapeutics	3.00	Buy	$10.00	99.44% Upside
MRSN Mersana Therapeutics	3.00	Buy	$56.60	638.52% Upside
XLO Xilio Therapeutics	3.33	Buy	$3.00	329.18% Upside

Current Analyst Ratings Breakdown

Latest DWTX, XLO, CLNN, and MRSN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
8/18/2025	CLNN Clene	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$83.00 ➝ $48.00
8/14/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
8/14/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$250.00 ➝ $36.00
8/14/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$125.00 ➝ $30.00
8/13/2025	MRSN Mersana Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
8/6/2025	XLO Xilio Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	XLO Xilio Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$2.00
7/18/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
6/30/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
6/3/2025	MRSN Mersana Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLNN Clene	$340K	156.46	N/A	N/A	($1.06) per share	-5.02
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	($7.56) per share	N/A
MRSN Mersana Therapeutics	$34.77M	1.10	N/A	N/A	($1.92) per share	-3.99
XLO Xilio Therapeutics	$6.34M	5.71	N/A	N/A	$0.40 per share	1.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLNN Clene	-$39.40M	-$3.76	N/A	N/A	N/A	-10,386.36%	N/A	-125.49%	11/12/2025 (Estimated)
DWTX Dogwood Therapeutics	-$12.35M	-$18.78	N/A	N/A	N/A	N/A	N/A	-27.41%	11/6/2025 (Estimated)
MRSN Mersana Therapeutics	-$69.19M	-$14.62	N/A	N/A	N/A	-212.94%	-990.16%	-54.85%	11/12/2025 (Estimated)
XLO Xilio Therapeutics	-$58.24M	-$0.76	N/A	N/A	N/A	-374.79%	-399.15%	-58.68%	11/6/2025 (Estimated)

Latest DWTX, XLO, CLNN, and MRSN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CLNN Clene	-$0.49	-$0.78	-$0.29	-$0.78	$0.06 million	$0.03 million
8/14/2025	Q2 2025	XLO Xilio Therapeutics	-$0.08	-$0.16	-$0.08	-$0.16	$8.21 million	$8.21 million
8/13/2025	Q2 2025	DWTX Dogwood Therapeutics	-$1.26	-$1.99	-$0.73	-$1.99	N/A	N/A
8/13/2025	Q2 2025	MRSN Mersana Therapeutics	-$3.75	-$4.08	-$0.33	-$4.87	$6.06 million	$3.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLNN Clene	N/A	N/A	N/A	N/A	N/A
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLNN Clene	N/A	1.58	1.57
DWTX Dogwood Therapeutics	N/A	7.80	7.80
MRSN Mersana Therapeutics	N/A	1.35	1.35
XLO Xilio Therapeutics	N/A	2.32	2.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLNN Clene	23.28%
DWTX Dogwood Therapeutics	9.05%
MRSN Mersana Therapeutics	93.92%
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
CLNN Clene	35.30%
DWTX Dogwood Therapeutics	3.90%
MRSN Mersana Therapeutics	13.00%
XLO Xilio Therapeutics	6.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLNN Clene	100	9.99 million	6.46 million	Optionable
DWTX Dogwood Therapeutics	5	1.91 million	1.84 million	N/A
MRSN Mersana Therapeutics	150	4.99 million	4.34 million	Optionable
XLO Xilio Therapeutics	70	51.83 million	48.56 million	Not Optionable

DWTX, XLO, CLNN, and MRSN Headlines

Recent News About These Companies

Leerink Partnrs Brokers Decrease Earnings Estimates for XLO

August 18, 2025 | americanbankingnews.com

XLO | Xilio Therapeutics Inc. Annual Cash Flow Statement | MarketWatch

August 16, 2025 | marketwatch.com

Xilio Therapeutics (NASDAQ:XLO) Rating Lowered to "Hold" at Wall Street Zen

August 16, 2025 | americanbankingnews.com

Xilio Therapeutics reports Q2 EPS (16c) vs (24c) last year

August 15, 2025 | msn.com

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

August 15, 2025 | taiwannews.com.twT

Xilio Revenue Jumps 246 Percent in Q2

August 15, 2025 | aol.comA

Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates

August 14, 2025 | zacks.com

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

August 14, 2025 | globenewswire.com

Leerink Partners Initiates Coverage of Xilio Therapeutics (XLO) with Outperform Recommendation

August 7, 2025 | msn.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 1, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - Morningstar

July 3, 2025 | morningstar.comM

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 2, 2025 | globenewswire.com

James Samuel Shannon Acquires 25,000 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) Stock

June 19, 2025 | insidertrades.com

Xilio Therapeutics expands board, elects new director

June 12, 2025 | investing.com

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of Directors

June 10, 2025 | quiverquant.comQ

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

June 10, 2025 | globenewswire.com

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

June 5, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2025 | globenewswire.com

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

June 2, 2025 | globenewswire.com

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite ...

June 2, 2025 | stockhouse.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX, XLO, CLNN, and MRSN Company Descriptions

Clene NASDAQ:CLNN

$5.32 -0.34 (-5.92%)

As of 04:00 PM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Dogwood Therapeutics NASDAQ:DWTX

$5.01 +0.06 (+1.29%)

As of 03:58 PM Eastern

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Mersana Therapeutics NASDAQ:MRSN

$7.60 -0.14 (-1.87%)

As of 04:00 PM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Xilio Therapeutics NASDAQ:XLO

$0.70 0.00 (-0.58%)

As of 04:00 PM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time